


# Figure S1:



**Figure S1. HIF-1 $\alpha$  siRNA decreases the protein level of HIF-1 $\alpha$  in irinotecan (IR)-treat HepG2 cells.** (A) Western blot analysis of HIF-1 $\alpha$  protein level in HepG2 cells. (B) Densitometric quantification of HIF-1 $\alpha$ . The blots were cut prior to hybridisation with indicated primary antibodies. Data are presented as mean  $\pm$  SD (n = 3), \*P < 0.05 compared with normal control group, \*\*P < 0.01 compared with Scra group. Scra: scrambled.

# Table S1:

Table S1. Antibody information for western blot.

<b>Antibody Name</b>	<b>Company and City</b>	<b>Dilution Degree</b>
HIF-1 $\alpha$	Gene Tex, Irvine, CA, USA	1:2000
NLRP3	Affinity Biosciences, Cincinnati, OH, USA	1:1000
LC-3I/II	Abcam, Cambridge, MA, USA	1:1000
p62	Abcam, Cambridge, MA, USA	1:1000
BNIP3	Bioss, Beijing, China	1:1000
SREBP-1c	Bioss, Beijing, China	1:1000
IL-1 $\beta$	Protein Tech Group, Wuhan, China	1:1000
Beclin1	Protein Tech Group, Wuhan, China	1:5000
cleaved Caspase-1	Protein Tech Group, Wuhan, China	1:1000
$\beta$ -actin	Protein Tech Group, Wuhan, China	1:5000
anti-Mouse IgG	Beyotime, Haimen, China	1:1000
anti-Rabbit IgG	Beyotime, Haimen, China	1:1000